Supernus and Indivior Forge a $2.2B CNS Powerhouse Through Merger of Equals, Backed by a $1B Special Dividend
SUPN sits 45% above its 52-week low of $32.83.
Summary
Supernus and Indivior are merging in an all-stock deal, creating a CNS biopharma leader with $2.2B in combined revenue. Indivior stockholders get a $1B special dividend; Supernus stockholders get 1.5401 Indivior shares per share. The combined company will be led by Supernus CEO Jack Khattar.
Key Events · M&A and Partnerships · SUPN
-
Merger of Equals Signed
On August 1, 2026, Supernus and Indivior signed a definitive merger agreement. Each Supernus share will be converted into 1.5401 Indivior shares, resulting in Supernus stockholders owning approximately 43.5% of the combined company on a fully diluted basis.
-
$1 Billion Special Dividend
Immediately before closing, Indivior will pay a $1 billion cash dividend to its stockholders, funded by a $650 million term loan from Citibank and existing cash. This represents a significant return of capital to Indivior holders.
-
Leadership and Governance
Jack Khattar (Supernus CEO) will lead the combined company as President and CEO; Tony Kingsley (Indivior director) will serve as Board Chair. The 8-member board will be evenly split between the two companies.
-
Financial Impact and Synergies
The combined company expects pro forma revenues of approximately $2.2 billion and $125 million in annual cost synergies. Pro forma net leverage is under 1x, providing financial flexibility for growth.
Analysis · SUPN · Life Sciences
A definitive all-stock merger of equals will unite Supernus Pharmaceuticals and Indivior Pharmaceuticals, creating a CNS-focused biopharma leader with pro forma revenues of approximately $2.2 billion. Structured as a tax-free reorganization, the deal converts each Supernus share into 1.5401 Indivior shares, giving Supernus stockholders about 43.5% of the combined company. Immediately before closing, Indivior will pay a $1 billion special cash dividend to its stockholders, funded by $650 million in new debt and existing cash. The combined company will be led by Supernus CEO Jack Khattar, with Indivior's Tony Kingsley as board chair. Both boards have unanimously approved the transaction, and directors and executive officers of both companies have entered into voting agreements to support the deal. The merger is expected to close in Q4 2026, subject to stockholder and regulatory approvals. This is a thesis-altering event that reshapes both companies' futures, creating a scaled CNS leader with significant synergy potential and a strong balance sheet.
At the time of this filing, SUPN was trading at $47.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $32.83 to $59.68. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.